The cost-of-illness of multiple sclerosis in Jordan
Expert Review of Pharmacoeconomics & Outcomes Research · 07.02.2025 · 25 (2) · 179-186
DOI: 10.1080/14737167.2024.2406797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 23.09.2024. Verfasst von Ibrahim Alabbadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Cost of Illness, Multiple Sclerosis, Health Care Costs, Delivery of Health Care. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Multiple Sclerosis (MS) imposes a significant financial burden on health-care systems. This study aims to determine the cost-of-illness (COI) for MS in Jordan, a country where data on the economic impact of MS are scarce. METHODS: Data were collected for one year, annual COI was estimated using a cross-sectional snowball sampling design. Eligible patients completed a self-reported questionnaire to provide sociodemographic, physician visit, and diagnostic and laboratory test data. Indirect costs were estimated using an adjusted Human Capital Approach. RESULTS: This study included 383 patients, (73% females, 61% between 26-45). Eighty % took disease-modifying therapies (DMTs), and 40% had relapses in that year. One-third use non-DMTs and equipment for assistance. The average annual cost per patient was $11,719 (direct costs=$11,252, indirect costs=$467). The total annual cost for all participants was $748,299. The estimated cost of non-DMT, medical tools, diagnostic tests, and hospitalization per patient was $53, 51, 99, and 235 respectively. CONCLUSION: High costs of DMTs state the necessity of resource optimization in Jordan public healthcare facilities. Such findings yield policy-informing actionable insights, suggesting strategic investments in more cost-effective DMTs with potential improvement in accessibility and reduction in the overall economic burden faced by both patients and governments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, University of Jordan, Amman, Jordan.
- Faculty of Economics, Yarmouk University, Irbid, Jordan.
- International Society for Pharmacoeconomics and Outcomes Research, Amman, Jordan.
- Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
- Clinical Pharmacy Department, Jordan University Hospital, Amman, Jordan.
- Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
ORCID-Profile: Sara Al-Ajlouny
Zitieren
APA
Alabbadi, I., Al-Ajlouny, S., Alsoud, Y., BaniHani, A., Arar, B. A., Massad, E. M., Muflih, S., & Shawawrah, M. (2025). The cost-of-illness of multiple sclerosis in Jordan. Expert Review of Pharmacoeconomics & Outcomes Research, 25(2), 179-186. https://doi.org/10.1080/14737167.2024.2406797
Vancouver
Alabbadi I, Al-Ajlouny S, Alsoud Y, BaniHani A, Arar BA, Massad EM, et al. The cost-of-illness of multiple sclerosis in Jordan. Expert Review of Pharmacoeconomics & Outcomes Research. 2025;25(2):179-186. doi:10.1080/14737167.2024.2406797
BibTeX
@article{Alabbadi2025,
author = {Alabbadi, Ibrahim and Al-Ajlouny, Sara and Alsoud, Yazan and BaniHani, Ayah and Arar, Bayan A and Massad, Eman M and Muflih, Suhaib and Shawawrah, Mays},
title = {The cost-of-illness of multiple sclerosis in Jordan},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
volume = {25},
number = {2},
pages = {179--186},
doi = {10.1080/14737167.2024.2406797}
}
EUVIMED